Key result
Cardioversion of acute atrial fibrillation without anticoagulation carries a low risk of thromboembolic events in patients without risk factors, but a risk of approximately 10% in those with multiple risk factors.
Why the study?
Does cardioversion without anticoagulation increase the risk of thromboembolic events in patients with acute atrial fibrillation?
Does cardioversion without anticoagulation increase the risk of thromboembolic events in patients with acute atrial fibrillation?
Cardioversion of acute atrial fibrillation without anticoagulation is safe only in patients without stroke risk factors, while those with multiple risk factors face a high risk of thromboembolism and require anticoagulation.
Answers are grounded in this paper and cite their sources.
May support selective anticoagulation omission before acute AF cardioversion in low-risk patients; leaves open prospective validation in those with multiple risk factors.
A major concern in cardioversion of newly detected atrial fibrillation is the risk of thromboembolic events. The vast majority of these events occur in the first week following cardioversion. Transesophageal echocardiography has demonstrated that thrombus and dense spontaneous echo contrast may occur in the left atrium and left atrial appendage in patients with acute atrial fibrillation (<48 hours) scheduled for cardioversion. Moreover, atrial function may become impaired immediately following successful cardioversion. The risk of thromboembolic events increases with the presence of stroke risk factors, such as heart failure, hypertension, diabetes, prior stroke, female sex and age above 65-75 years. Thus, the current guidelines of the ESC and ACC/AHA/Heart Rhythm Society recommend that patients with acute atrial fibrillation should undergo cardioversion under cover of unfractionated or low-molecular weight heparin followed by oral anticoagulation for at least 4 weeks in patients in patients at moderate-to-high risk for stroke. In line with the guidelines, new evidence from a large patient population suggests that after successful cardioversion of acute atrial fibrillation, patients have a low overall risk of thromboembolic events without any anticoagulation when they have no risk factors for thromboembolism. In contrast, the risk is in the range of 10% in patients with multiple classic risk factors for thromboembolism.
No takes yet. Share an insight, caveat, or question.
Airaksinen et al. (2013) conducted a review in Acute atrial fibrillation. Cardioversion without anticoagulation was evaluated on Thromboembolic events. Cardioversion of acute atrial fibrillation without anticoagulation carries a low risk of thromboembolic events in patients without risk factors, but a risk of approximately 10% in those with multiple risk factors.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: